Pregnancy Outcome Following Exposure to Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Antagonists
Top Cited Papers
- 1 August 2012
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 60 (2), 444-450
- https://doi.org/10.1161/hypertensionaha.112.196352
Abstract
The objective was to analyze the outcome following prenatal exposure to angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor antagonists (ARBs). For this purpose, a systematic review of published case reports and case series dealing with intrauterine exposure to ACE-Is or to ARBs using Medline as the source of data was performed. The publications retained for analysis included patients who were described individually, revealing, at minimum, the gestational age, substance used, period of medication intake, and the outcome. In total, 72 reports were included; 37 articles (118 well-documented cases) described the prenatal exposure to ACE-Is; and 35 articles (68 cases) described the prenatal exposure to ARBs. Overall, 52% of the newborns exposed to ACE-Is and 13% of the newborns exposed to ARBs did not exhibit any complications ( P <0.0001). Neonatal complications were more frequent following exposure to ARBs and included renal failure, oligohydramnios, death, arterial hypotension, intrauterine growth retardation, respiratory distress syndrome, pulmonary hypoplasia, hypocalvaria, limb defects, persistent patent ductus arteriosus, or cerebral complications. The long-term outcome is described as positive in only 50% of the exposed children. Fetopathy caused by exposure to ACE-Is or ARBs has relevant neonatal and long-term complications. The outcome is poorer following exposure to ARBs. We propose the term “fetal renin-angiotensin system blockade syndrome” to describe the related clinical findings. Thirty years after the first description of ACE-I fetopathy, relevant complications are, at present, regularly described, indicating that the awareness of the deleterious effect of prenatal exposure to drugs inhibiting the renin-angiotensin system should be improved.Keywords
This publication has 71 references indexed in Scilit:
- Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockersReproductive Toxicology, 2011
- Reversible fetal renal failure after maternal treatment with Candesartan: A case reportReproductive Toxicology, 2010
- Angiotensin II receptor antagonists against migraine in pregnancy: fatal outcomeThe Journal of Headache and Pain, 2010
- Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blockerPediatric Nephrology, 2007
- Angiotensin-converting enzyme inhibitor fetopathy: long-term outcomeArchives of Disease in Childhood: Fetal & Neonatal, 2007
- Non-lethal fetal toxicity of the angiotensin receptor blocker candesartanPediatric Nephrology, 2006
- Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonistsPediatric Nephrology, 2006
- Increased renal echogenicity in a preterm neonate: QuestionPediatric Nephrology, 2005
- CONGENITAL RENAL DYSGENESIS POSSIBLY DUE TO CAPTOPRILThe Lancet, 1989